ARGX: argenx N.V. Price to Sales
argenx SE (ARGX) leads the development of autoimmune pathology therapies by utilizing unique llama antibodies. Stringent FDA oversight and patent protection establish a robust barrier to entry for competitors. The global launch of drugs is accelerating profit growth and the return on investment for R&D. The revenue multiple trend illustrates the market's revaluation of the business, with the indicator reaching 11.80.
Analytical breakdowns for Argenx (ARGX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ARGX - Company Net Income|Company Profit Forecast argenx SE|ARGX - P/E Multiple|Projected Price to Earnings Ratio argenx N.V.|ARGX - PEG Multiple|EV/EBITDA Multiple Argenx|ARGX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year argenx|ARGX - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year argenx.com|ARGX - Net earnings per share growth this year|Projected earnings per share growth rate for next year argenx SE
- total revenue and sales volume data:
Fundamental company analysis:argenx.com (ARGX)
When screening issuer reliability, this indicator compares market capitalization to sales volume to determine how much an investor pays per unit of revenue. The ratio of company value to annual revenue allows for an assessment of the commercialization efficiency of argenx SE drugs, excluding the impact of acquisition costs and focusing on the returns from technological antibody licensing alliances.
Who argenx SE competes with
biontech.de - Market Cap to Revenue Ratio|P/S Multiple ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Price to Sales|Protagonist Therapeutics Inc - P/S Multiple|IMVT - P/S Multiple|Kiniksa Pharmaceuticals (KNSA) - Price-to-Revenue Ratio|grifols.com - Market Capitalization-to-Revenue Ratio|ADPT (Adaptive Biotechnologies Corporation) - P/S Multiple|CLDX - Price-to-Revenue Multiple|P/S Multiple AUPH|BCRX - Price to Sales|Price-to-Revenue Ratio Vera Therapeutics, Inc. VERA|DNTH: Market Cap to Revenue Ratio|PHVS: Market Cap to Revenue|ABCL (AbCellera Biologics Inc.) - Market Cap to Revenue Ratio|TRML (Tourmaline Corp) - Market Cap to Revenue|Precigen Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Pharming Group N.V.|nektar.com (NKTR) - Price-to-Revenue Coefficient|P/S Multiple UPB|ZBIO - Price to Sales|P/S Multiple IMNM (Immunome Corp)|P/S Multiple Gossamer Bio Corp. GOSS|KALV - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|PVLA: P/S Multiple|Price-to-Revenue Multiple Savara Inc SVRA|Market Cap to Revenue RIGL|Market Cap to Revenue Ratio ANAB (AnaptysBio Inc.)|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN: Price-to-Sales Ratio|P/S Multiple RAPT (RAPT Therapeutics)|Market Capitalization-to-Revenue Ratio JBIO|Aclaris - P/S Multiple|KYTX - P/S Multiple|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|cabalettabio.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Market Cap to Revenue Theratechnologies, Inc. (THTX)|P/S Multiple AVTX|P/S Multiple Eledon Pharmaceuticals, Inc (ELDN)|Agenus - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CLYM|Zura Bio - P/S Multiple|Price-to-Revenue Coefficient aTyr Pharma Inc ATYR|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Equillium Bio (EQ)|Market Cap to Revenue CNTB (Connect Biopharma)|P/S Multiple immunic-therapeutics.com (IMUX)|Price-to-Revenue Ratio Atara Bio ATRA|IFRX: Market Cap to Revenue Ratio|X4 Pharmaceuticals - P/S Multiple|Price to Sales Adicet Bio|CELU: P/S Multiple|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|akaritx.com (AKTX) - Price-to-Revenue Multiple|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Price to Sales|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO (iBio, Inc.) - Market Cap to Revenue|Market Cap to Revenue Ratio CARM|Market Cap to Revenue XTLB|BOLT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Price-to-Revenue Coefficient aptevotherapeutics.com|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI Bio - P/S Multiple|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|SCNI - Price-to-Revenue Multiple|Market Cap to Revenue CALI (CalciMedica, Inc.)|affimed.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Price-to-Sales Ratio|IGM Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
